Goodwin Procter advised Global Blood Therapeutics on the deal.Global Blood Therapeutics, Inc. (Nasdaq: GBT) announced its offering of 1.875% Convertible Senior Notes due 2028. The deal…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Martina Bellini
…
This content is for Standard 1 Year members only. LoginJoin Now